Related Experiment Videos
Malignant hypertension in a child with hemolytic-uremic syndrome treated with captopril
Acta Paediatrica Scandinavica
|July 1, 1981
Insights
Malignant hypertension in a child with hemolytic-uremic syndrome was effectively treated with Captopril. This intervention allowed for discontinuation of dialysis and recovery of kidney function.
Area of Science:
- Pediatric Nephrology
- Cardiovascular Pharmacology
Background:
- Hemolytic-uremic syndrome (HUS) can lead to severe complications, including malignant hypertension.
- Malignant hypertension poses a significant risk to vital organs, particularly the kidneys.
Observation:
- A 5-year-old boy presented with malignant hypertension secondary to HUS.
- The patient required intensive management, including hemodialysis.
Findings:
- Oral Captopril, an angiotensin-1-converting enzyme inhibitor, successfully controlled the malignant hypertension.
- Hemodialysis was discontinued after two months of treatment.
- Glomerular filtration rate (GFR) improved to 63 ml/min/1.73 m2 within 11 months post-acute phase.
Implications:
- Captopril offers a viable therapeutic option for managing HUS-associated malignant hypertension in children.
- Early intervention with ACE inhibitors may prevent long-term renal damage.
- This case highlights the potential for significant recovery of renal function following HUS.
Abstract:
A 5-year-old boy is presented suffering from malignant hypertension due to hemolytic-uremic syndrome. Captopril, an oral angiotensin-1-converting enzyme inhibitor, was able to curb the natural course of the malignant hypertension. Haemodialysis could be discontinued after 2 months. The glomerular filtration rate recovered to 63 ml/min/1.73 m2 11 months after the acute phase.